EUVIMEDEUVIMED entdecken
Crossref

Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung

Katsuhiro Masago, Hiroaki Kuroda, Katsutoshi Seto, Eiichi Sasaki, Yasuko Fujita, Yoshitsugu Horio, Shiro Fujita, Hirokazu Matsushita

Clinical Lung Cancer · 2025-11 · 26 (7) · 583-594.e4

DOI: 10.1016/j.cllc.2025.06.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025-11. Verfasst von Katsuhiro Masago und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer…. Hauptthemen laut MEDLINE: Adenocarcinoma, Mucinous, Lung Neoplasms, Biomarkers, Tumor, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive mucinous adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma, accounting for 3%-10% of cases. It is often associated with KRAS mutations or, in nonsmokers, NRG1 fusions. Approximately 20% of IMAs have unclear genomic backgrounds. This study aimed to clarify the genomic etiology of these cases through a retrospective molecular analysis and RNA sequencing. PATIENTS AND METHODS: This study analyzed 107 cases of NSCLC that were treated by surgical resection at Aichi Cancer Center from 2009 to 2023, with a focus on IMAs. For cases with unclear genomic backgrounds, RNA sequencing was conducted to identify potential driver gene alterations, and the results were compared to those of known KRAS-positive cases. Statistical analyses, including Cox regression and Kaplan-Meier analyses, were used to evaluate risk factors, recurrence-free survival, and the prognosis. RESULTS: In this study, 107 cases of resected IMA were analyzed. KRAS mutations were found in 70.1% of cases, followed by NRG1 fusions (9.2%), and other mutations. A novel fusion gene, ATP6V1H::LYN, was discovered in 1 case. RNA sequencing and a gene set enrichment analysis revealed distinct molecular pathways in KRAS-positive tumors, including the activation of oxidative phosphorylation and TNFα-NF-κB signaling. Tumors with no driver gene alterations exhibited a higher frequency of copy number variations and tumor mutational burden than KRAS and NRG fusion-positive cases. CONCLUSION: IMAs are characterized by relatively higher incidences of harboring KRAS mutations and NRG fusion genes, revealing potential therapeutic targets including druggable mutations and immune-related markers, while highlighting the heterogeneous genomic background and utility of RNA sequencing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma, MucinousLung NeoplasmsBiomarkers, TumorAdenocarcinoma of LungHumansMaleFemaleMiddle AgedRetrospective StudiesMutationAgedPrognosisProto-Oncogene Proteins p21(ras)GenomicsAdultNeuregulin-1Survival Rate

Stichwörter der Autor:innen

Fusion geneKRASLung cancerNRG1RNA sequence

Substanzen

Proto-Oncogene Proteins p21(ras)Biomarkers, TumorKRAS protein, humanNRG1 protein, humanNeuregulin-1

Autor:innen und Institutionen

  • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan. Electronic address: masago@a…
  • Department of Thoracic Surgery, Teikyo University Mizonokuchi Hospital, Kanagawa, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan.
  • Department of Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan.
  • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan.
  • Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.
  • Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan; Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Aichi, Japan.

Zitieren

APA

Masago, K., Kuroda, H., Seto, K., Sasaki, E., Fujita, Y., Horio, Y., Fujita, S., & Matsushita, H. (2025). Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. Clinical Lung Cancer, 26(7), 583-594.e4. https://doi.org/10.1016/j.cllc.2025.06.004

Vancouver

Masago K, Kuroda H, Seto K, Sasaki E, Fujita Y, Horio Y, et al. Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung. Clinical Lung Cancer. 2025;26(7):583-594.e4. doi:10.1016/j.cllc.2025.06.004

BibTeX
@article{Masago2025,
  author = {Masago, Katsuhiro and Kuroda, Hiroaki and Seto, Katsutoshi and Sasaki, Eiichi and Fujita, Yasuko and Horio, Yoshitsugu and Fujita, Shiro and Matsushita, Hirokazu},
  title = {Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung},
  journal = {Clinical Lung Cancer},
  year = {2025},
  volume = {26},
  number = {7},
  pages = {583--594.e4},
  doi = {10.1016/j.cllc.2025.06.004}
}
Kostenlos starten →